Costs
Alexion OneSource CoPay Program Terms and Conditions The Alexion OneSource™ Copay Program (the “Program”) pays for eligible out-of-pocket medication and infusion costs associated with Soliris® (eculizumab) or ULTOMIRIS® (ravulizumab-cwvz) up to $15,000 US dollars per calendar year. Prescription medication related to prescribed treatment LLS can pay your provider directly or reimburse you for payments already made. You have complete freedom to choose doctors, providers, suppliers, insurance companies and treatment-related medications. .Pay as little as $30 per prescription of Vyvanse (lisdexamfetamine dimesylate) for a maximum of up to $60 savings per prescription. The offer covers the amount above $30 up to a maximum of $60 savings per prescription. You will be responsible for any additional cost above $90 for each prescription. Restrictions may apply. Level assigned to your drug. Once you and your plan spend $4,130 combined on drugs (including deductible), you’ll pay no more than 25% of the cost for prescription drugs until your out-of-pocket spending is $6,550, under the standard drug benefit. Manufacturer copay cards can be powerful tools for patients on plans with high deductibles, high copays, or very limited drug formularies, but also for patients with rare or complex diseases. Many maintenance medications for illnesses like HIV and hepatitis C do not have generic alternatives and can be very expensive.
Find your TRICARE costs, including copayments,enrollment fees, and payment options.
- Most costs are for calendar year 2021 unless noted separately.
- For US Family Health Plan and TRICARE Prime Remote costs, choose 'TRICARE Prime' from the pull-down menu
- Visit the Cost Terms page for definitions to help you better understand TRICARE costs.
- If you're an unremarried former spouse, for the Continued Health Care Benefit Program (CHCBP), chose 'Retired' regardless of your sponsor's status
- Looking for dental costs? Visit the TRICARE Dental Costs section.
Help Paying For Medication Copays
Medication Copays
Copay Medication Adherence
Copayments will be waived retroactively to March 18 for certain testing and office visits related to the testing. The test must be one approved, cleared, or authorized by the Food and Drug Administration to detect SARS-CoV-2 or diagnose COVID-19. If you paid any copayments for testing related to COVID-19 and the resulting office visits with a network or non- network provider, you may file a claim for reimbursement. For more information related to the coronavirus, visit the FAQ page.